Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist administered once weekly, produces substantial, sustained, and dose-dependent weight loss in adults with obesity, significantly outperforming placebo, semaglutide, and dulaglutide.
If you have obesity, Tirzepatide is a highly effective, once-weekly injection that helps you lose a significant amount of weight (up to 20% or more) by targeting the hormones that control hunger and fullness. It works better than other similar drugs and lifestyle changes alone. While it can cause temporary stomach issues like nausea, these usually get better over time. It is a long-term treatment for a chronic condition.
Administration of tirzepatide once weekly provides a substantial and sustained reduction in bodyweight with little side effects... Clinical trials showed both high efficacy and safety of Tirzepatide in management of obesity. Due to its novel, broadened mechanism of action it seems to be the most effective drug for reducing bodyweight available on the market.
Why this rating
Based on multiple Phase 3 randomized, double-blind, placebo-controlled trials (SURMOUNT-1, SURPASS-1, SURPASS-2).
Source
Tirzepatide - a novel dual GLP-1 and GIP receptor agonist used in pharmacotherapy of obesity: A literature review
Bartłomiej STACHYRA et al. · Journal of Education Health and Sport · 2023
DOI 10.12775/jehs.2023.18.01.003
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →